Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;14(5):768-783.
doi: 10.1016/j.jtho.2019.01.022. Epub 2019 Feb 11.

2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer

Stefan Zimmerman  1 , Arundhati Das  2 , Shuhang Wang  3 , Ricklie Julian  4 , Leena Gandhi  4 , Juergen Wolf  5
Affiliations
Free article
Review

2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer

Stefan Zimmerman et al. J Thorac Oncol. 2019 May.
Free article

Abstract

SCLC remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently programmed death ligand 1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended-disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored immunotherapy and targeted therapies based on specific biomarkers and rational combinations. Here we discuss the preclinical and clinical strides in 2017 and 2018 that put us on the threshold of a new era in therapeutics and will, it is hoped, translate into significant improvements in survival.

Keywords: Biomarkers; Immunotherapy; Novel therapeutics; Small cell lung cancer.

PubMed Disclaimer

MeSH terms